The effect of CXCR1 and CXCR2 inhibitor on the Ac-PGP mediated MMP-9 release in PMNs.

Abstract

<p>PMNs were pretreated with the CXCR1 and CXCR2 inhibitor repertaxin at different dose for 20 minutes and then stimulated with Ac-PGP (1.0 mg/ml) for 30 minutes. Cell-free supernatants were collected for MMP-9 assay. The levels of ERK1/2 MAPK activation were determined by western blot analysis of lysates from stimulated PMNs with actin controls which paralleled total ERK 1/2. Phosphorylated ERK1/2 MAPK was determined using the anti-ERK antibody that recognizes phosphorylated threonine and tyrosine residues (Thr202/Tyr204). <b>A</b>. The detection of gelatinolytic activity by g<i>elatin zymography</i> representative of three gels. <b>B</b>. The quantification of MMP-9 activity by ELISA-based assay. <b>C</b>. Total and phosphorylated level of ERK1/2 MAPK representative of three gels <b>D</b>. Fold change of phosphorylation of ERK1/2 MAPK versus total ERK1/2 MAPK normalized to PMN control. *p<0.05 compared to Ac-PGP without inhibitor pretreatment.</p